These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 729609)

  • 21. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Heel RC; Lewis SP
    Drugs; 1986 Dec; 32(6):481-508. PubMed ID: 2878798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine.
    D'Amato RJ; Largent BL; Snowman AM; Snyder SH
    J Pharmacol Exp Ther; 1987 Jul; 242(1):364-71. PubMed ID: 3475452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients.
    Oyehaug E; Ostensen ET; Salvesen B
    J Chromatogr; 1984 Jun; 308():199-208. PubMed ID: 6589233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amiodarone pharmacokinetics.
    Holt DW; Tucker GT; Jackson PR; Storey GC
    Am Heart J; 1983 Oct; 106(4 Pt 2):840-7. PubMed ID: 6613830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro.
    Hyttel J
    Psychopharmacology (Berl); 1978 Dec; 60(1):13-8. PubMed ID: 104340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes.
    Plenge P; Mellerup ET
    Eur J Pharmacol; 1985 Dec; 119(1-2):1-8. PubMed ID: 2935414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions.
    Arnt J; Hyttel J; Overø KF
    Pol J Pharmacol Pharm; 1984; 36(2-3):221-30. PubMed ID: 6591152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics of amiodarone.
    Latini R; Tognoni G; Kates RE
    Clin Pharmacokinet; 1984; 9(2):136-56. PubMed ID: 6370540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram.
    Arnt J; Overø KF; Hyttel J; Olsen R
    Psychopharmacology (Berl); 1984; 84(4):457-65. PubMed ID: 6441945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and biotransformation of benzbromarone in man.
    Ferber H; Vergin H; Hitzenberger G
    Eur J Clin Pharmacol; 1981; 19(6):431-5. PubMed ID: 7250176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics and bioavailability of mexiletine in healthy subjects.
    Häselbarth V; Doevendans JE; Wolf M
    Clin Pharmacol Ther; 1981 Jun; 29(6):729-36. PubMed ID: 7226704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.
    Stäubli M; Troendle A; Schmid B; Balmer P; Kohler B; Studer H; Bircher J
    Eur J Clin Pharmacol; 1985; 29(4):417-23. PubMed ID: 4092724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereoselective disposition of mexiletine in man.
    Grech-Belanger O; Turgeon J; Gilbert M
    Br J Clin Pharmacol; 1986 May; 21(5):481-7. PubMed ID: 3718807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients.
    Bjerkenstedt L; Edman G; Flyckt L; Hagenfeldt L; Sedvall G; Wiesel FA
    Psychopharmacology (Berl); 1985; 87(3):253-9. PubMed ID: 3936081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absorption, distribution and elimination of mexiletine.
    Prescott LF; Pottage A; Clements JA
    Postgrad Med J; 1977; 53 Suppl 1():50-5. PubMed ID: 876954
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics and body distribution of amiodarone in man.
    Plomp TA; van Rossum JM; Robles de Medina EO; van Lier T; Maes RA
    Arzneimittelforschung; 1984; 34(4):513-20. PubMed ID: 6540111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orthostatic side effects of clomipramine and citalopram during treatment for depression.
    Christensen P; Thomsen HY; Pedersen OL; Gram LF; Kragh-Sørensen P
    Psychopharmacology (Berl); 1985; 86(4):383-5. PubMed ID: 3929308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability and pharmacokinetics of ketanserin in elderly subjects.
    Kurowski M
    Eur J Clin Pharmacol; 1985; 28(4):411-7. PubMed ID: 3161741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoxetine kinetics and protein binding in normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Pottratz ST; Sloan RS; Wolen RL; Lemberger L
    Clin Pharmacol Ther; 1984 Jul; 36(1):138-44. PubMed ID: 6610522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acceleration of amiodarone elimination by cholestyramine].
    Nitsch J; Lüderitz B
    Dtsch Med Wochenschr; 1986 Aug; 111(33):1241-4. PubMed ID: 3743429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.